Oric(US:ORIC) Globenewswire·2026-03-17 21:01Core Insights - ORIC Pharmaceuticals announced that multiple abstracts on rinzimetostat, a selective allosteric inhibitor of PRC2 for prostate cancer treatment, have been accepted for presentation at the 2026 AACR Annual Meeting [1] Group 1: Abstract Presentation Details - The poster presentations will take place on April 22, 2026, from 9:00 a.m. to 12:00 p.m. PT, focusing on novel strategies to reverse drug resistance [2] - One of the abstracts highlights rinzimetostat's effectiveness in preclinical studies against PRC2 methyltransferase-resistant settings [2] Group 2: Abstract Highlights - Rinzimetostat has shown best-in-class efficacy and safety in combination with androgen receptor (AR) inhibitors, maintaining potent inhibition of PRC2 complexes in various resistance contexts [3][5] - Preclinical studies indicate that rinzimetostat retains antitumor activity in prostate cancer cells overexpressing EZH1, while traditional EZH2 inhibitors lose potency [3] - Rinzimetostat effectively inhibits H3K27me3 in prostate cancer cells with acquired resistance mutations, suggesting its potential superiority in resistant contexts [3] Group 3: Clinical Development - A global phase 1b trial of rinzimetostat in combination with AR inhibitors is currently ongoing for metastatic prostate cancer [3][6] - The trial aims to evaluate the drug's ability to resensitize ARPI-resistant tumors to AR pathway inhibition [6] Group 4: Company Overview - ORIC Pharmaceuticals is focused on overcoming resistance in cancer, with rinzimetostat being a key candidate for prostate cancer treatment [7] - The company also develops enozertinib, targeting specific mutations in non-small cell lung cancer (NSCLC) [7]